Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial

Study Type – Decision analysis (based on alternative scenarios)

[1]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[2]  Yair Lotan,et al.  Statistical consideration for clinical biomarker research in bladder cancer. , 2010, Urologic oncology.

[3]  Y. Lotan,et al.  Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. , 2010, Urologic oncology.

[4]  Y. Lotan,et al.  Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. , 2009, The Journal of urology.

[5]  U. Capitanio,et al.  Impact of clinical factors, including a point‐of‐care nuclear matrix protein‐22 assay and cytology, on bladder cancer detection , 2009, BJU international.

[6]  Y. Lotan,et al.  Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. , 2008, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[7]  Y. Lotan,et al.  Screening for bladder cancer using urine-based tumor markers. , 2008, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[8]  A. Vickers.  Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular Markers , 2008, The American statistician.

[9]  Y. Lotan,et al.  Impact of risk factors on the performance of the nuclear matrix protein 22 point‐of‐care test for bladder cancer detection , 2008, BJU international.

[10]  Y. Lotan,et al.  Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma , 2008, BJU international.

[11]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[12]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  C. Roehrborn,et al.  Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. , 2006, The Journal of urology.

[14]  Edward Messing,et al.  Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. , 2006, JAMA.

[15]  Yair Lotan,et al.  Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. , 2005, The Journal of urology.

[16]  E. Messing,et al.  Detection of bladder cancer using a point-of-care proteomic assay. , 2005, JAMA.

[17]  A. Sagalowsky,et al.  Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. , 2004, European urology.

[18]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Dinney,et al.  Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional‐cell carcinoma of the bladder , 1999, Diagnostic cytopathology.

[20]  H. Grossman,et al.  Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. , 1998, The Journal of urology.

[21]  K Koiso,et al.  Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. , 1997, European urology.

[22]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[23]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[24]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.